Axsome Therapeutics (AXSM) Tops Q1 EPS by 8c

Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.22), $0.08 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $121.46 million versus the consensus estimate of $121.58 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.6% Yield
• ACI Worldwide exploring sale of billing division - Reuters